Aspirin and Dipyridamole

Aspirin and Extended-Release Dipyridamole Capsule is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. Aspirin and Extended-Release Dipyridamole Capsule is a combination of aspirin and dipyridamole, antiplatelet agents, indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis

The antithrombotic action of aspirin and extended-release dipyridamole is the result of the additive antiplatelet effects of dipyridamole and aspirin. Dipyridamole Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo, the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5 to 1.9 mcg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A 2 -receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3',5'-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). Dipyridamole inhibits phosphodiesterase (PDE) in various tissues.

Aspirin and Extended-Release Dipyridamole Capsules are not interchangeable with the individual components of aspirin and dipyridamole tablets. The recommended dose of Aspirin and Extended-Release Dipyridamole Capsules is one capsule given orally twice daily, one in the morning and one in the evening. Swallow capsules whole without chewing. Aspirin and Extended-Release Dipyridamole Capsules can be administered with or without food. One capsule twice daily (morning and evening) with or without food. In case of intolerable headaches during initial treatment, switch to one capsule at bedtime and low-dose aspirin in the morning, resume BID dosing within one week. Do not chew capsule. Not interchangeable with the individual components of aspirin and dipyridamole tablets. Dispense in this unit-of-use container

Hypersensitivity to any product ingredients. Patients with known allergy to NSAIDs. Patients with the syndrome of asthma, rhinitis, and nasal polyps

Aspirin and extended-release dipyridamole capsules increases the risk of bleeding. Avoid use in patients with severe hepatic or renal insufficiency. Interrupt aspirin and extended-release dipyridamole capsules 48 hours before using intravenous dipyridamole or other adenosinergic agents for stress testing

The following adverse reactions are discussed elsewhere in the labeling: Hypersensitivity Allergy Risk of Bleeding The most frequently reported adverse reactions (>10% and greater than placebo) were headache, dyspepsia, abdominal pain, nausea, and diarrhea

Co-administration with anticoagulants, antiplatelets, or NSAIDs can increase risk of bleeding. Decreased renal function can occur with co-administration with NSAIDs

Store at 25 ° C (77 ° F), excursions permitted to 15 ° to 30 ° C (59 ° to 86 ° F). Protect from excessive moisture.